Liu, Bin http://orcid.org/0000-0002-3168-8456
Dong, Xiaolong
Zheng, Chunwei http://orcid.org/0000-0002-2084-5567
Keener, David
Chen, Zexiang http://orcid.org/0000-0002-1584-2417
Cheng, Haoyang http://orcid.org/0000-0003-3313-9853
Watts, Jonathan K. http://orcid.org/0000-0001-5706-1734
Xue, Wen http://orcid.org/0000-0002-9797-8042
Sontheimer, Erik J. http://orcid.org/0000-0002-0881-0310
Funding for this research was provided by:
Fondation Leducq
Cystic Fibrosis Foundation
Article History
Received: 13 October 2022
Accepted: 15 August 2023
First Online: 14 September 2023
Competing interests
: E.J.S. is a co-founder and Scientific Advisory Board member of Intellia Therapeutics and a Scientific Advisory Board member at Tessera Therapeutics. The University of Massachusetts Chan Medical School has filed patent applications related to this work. All other authors have no competing interests.